YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Telix Pharmaceuticals Limited First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (br…
Telix Pharmaceuticals Limited (TLX) closed the last trading session at $11.34, gaining 4.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any gui…
FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. The designation recognizes the program's potential to address an important u…
Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful…
Telix Pharmaceuticals has delivered a very strong 185.1% share price gain over the past five years, yet the latest acquisition plans and product approvals leave a clear question about whether that journey is still backed by its cash flows.…
Telix Pharmaceuticals (ASX:TLX) has moved to lead a merger with ITM Isotope Technologies Munich SE, a radioisotope producer and radiopharmaceutical developer, in a transaction valued at up to A$2.35b. Telix Pharmaceuticals shares trade at…
Telix Pharmaceuticals Limited (NASDAQ:TLX) agreed on September 21 to acquire ITM Isotope Technologies Munich SE. The deal is worth up to $2.35 billion. Telix will pay $1.65 billion upfront, before cash and debt. A further $700 million foll…
Telix Pharmaceuticals (ASX: TLX) has agreed to acquire ITM Isotope Technologies Munich SE in a deal valued at US$2.35b. The transaction gives Telix control of a major global producer of medical radioisotopes used in cancer diagnosis and tr…
Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts. Continue Reading
Telix Pharmaceuticals (TLX) agreed to acquire Germany-based ITM Isotope Technologies Munich in a dea PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Two scientists in conversation, standing in laboratory] Solskin * Australian biotechnology company Telix Pharmaceuticals (TLX [https://seekingalpha.com/symbol/TLX]) has agreed to acquire Germany's ITM Isotope in a $1.65B deal, the compani…
Transformational merger reinforces Telix's long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, underpinned by commerci…
Company Logo The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceutical therapies. Oncology leads adoption,…
Telix Pharmaceuticals Limited Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatme…
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults an…
Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") advises that Dr. Christian Behrenbruch, Managing Director and Group CEO…
Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U…
Telix Pharmaceuticals Limited David Gill appointed Chair of the Telix Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair. Dr. Mark Nelson will continue…
Rising treasury and sovereign yields driven by persistent inflation concerns are forcing investors to think harder about where future growth might justify the extra risk. This is where fast-growing stocks with high insider ownership become…
With European bond yields pushing toward multi year highs on persistent inflation concerns, investors are again paying close attention to what they are actually paying for future cash flows. Higher discount rates tend to punish overhyped s…
Global demand tied to AI related investment is shaping trade and capital flows, and that is putting growth companies with clear earnings ambitions back in focus. Investors are searching for businesses that can convert this demand into real…
This article first appeared on GuruFocus. Revenue: $477 million, up 22% year-on-year. EBITDA: $52 million, up 146% year-on-year. Net Profit After Tax: $38 million, up 30% year-on-year. Precision Medicine Revenue: Approximately $390 million…
Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026.…
MELBOURNE, Australia and INDIANAPOLIS, Aug. 6, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:…
MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday…
Regeneron Pharmaceuticals reported past second-quarter 2026 results with revenue rising to US$4,290.7 million from US$3,675.6 million a year earlier, while net income slipped to US$1,296.9 million and diluted EPS from continuing operations…
Shares of Telix Pharmaceuticals Limited (TLX) have gained 7% over the past four weeks to close the last trading session at $10.92, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analyst…
Telix Pharmaceuticals Limited Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2. Consistent with previously r…
Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance fo…
Telix Pharmaceuticals Limited First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceutical the…
• First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). • LUTEON is the first Phase 3 study of a CAIX[2]-targeted radiopharmaceutical therapy in ccRCC MELBOURN…
Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Austra…
First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care and research delivered in collaboration with the Melbourne Theranostic Innovation Cent…
First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney. OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, build…
Telix Pharmaceuticals Limited FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States. FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care…